Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ensysce Biosciences (ENSC) Other Accumulated Expenses (2020 - 2025)

Historic Other Accumulated Expenses for Ensysce Biosciences (ENSC) over the last 6 years, with Q3 2025 value amounting to $1.5 million.

  • Ensysce Biosciences' Other Accumulated Expenses rose 22515.46% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year increase of 22515.46%. This contributed to the annual value of $548458.0 for FY2024, which is 114.3% up from last year.
  • Latest data reveals that Ensysce Biosciences reported Other Accumulated Expenses of $1.5 million as of Q3 2025, which was up 22515.46% from $1.0 million recorded in Q2 2025.
  • Over the past 5 years, Ensysce Biosciences' Other Accumulated Expenses peaked at $3.7 million during Q3 2021, and registered a low of $370186.0 during Q2 2024.
  • Its 5-year average for Other Accumulated Expenses is $1.6 million, with a median of $1.2 million in 2025.
  • In the last 5 years, Ensysce Biosciences' Other Accumulated Expenses surged by 88828.66% in 2021 and then plummeted by 7564.51% in 2023.
  • Over the past 5 years, Ensysce Biosciences' Other Accumulated Expenses (Quarter) stood at $3.4 million in 2021, then tumbled by 34.66% to $2.2 million in 2022, then crashed by 75.65% to $542260.0 in 2023, then rose by 1.14% to $548458.0 in 2024, then soared by 165.03% to $1.5 million in 2025.
  • Its Other Accumulated Expenses was $1.5 million in Q3 2025, compared to $1.0 million in Q2 2025 and $888498.0 in Q1 2025.